These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37217095)

  • 1. Substantiation of a clopidogrel metabolism-associated gene (CYP2C19) variation among healthy individuals.
    Yadav AK; Chakkumkollath AK; Helna A; Birla S; Thimmulappa RK; Shambu SK; Vishwanath P; Prashant A
    Indian Heart J; 2023; 75(5):343-346. PubMed ID: 37217095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.
    Subraja K; Dkhar SA; Priyadharsini R; Ravindra BK; Shewade DG; Satheesh S; Sridhar MG; Narayan SK; Adithan C
    Eur J Clin Pharmacol; 2013 Mar; 69(3):415-22. PubMed ID: 22955794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clopidogrel metabolism related gene polymorphisms in Chinese patients with acute coronary syndrome].
    Feng GX; Liang Y; Bai Y; Chen T; Liu X; Yang YM; Wang XY; Yang YJ; Zhu J
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Nov; 40(11):908-13. PubMed ID: 23363670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
    Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
    Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina.
    Kim HS; Chang K; Koh YS; Park MW; Choi YS; Park CS; Oh M; Kim EY; Shon JH; Shin JG; Seung KB
    Circ Cardiovasc Genet; 2013 Oct; 6(5):514-21. PubMed ID: 24019397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention.
    Hwang SJ; Jeong YH; Kim IS; Koh JS; Kang MK; Park Y; Kwak CH; Hwang JY
    Thromb Res; 2011 Jan; 127(1):23-8. PubMed ID: 21075428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the INNOVANCE PFA P2Y assay and its association with CYP2C19 genotypes.
    Kim H; Kim Y; Koh YS; Lee HK; Chae H; Jekarl DW; Lee JM; Shin WS; Kim TH
    Platelets; 2015; 26(2):148-53. PubMed ID: 24617511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2.
    Watanabe H; Morimoto T; Ogita M; Suwa S; Natsuaki M; Suematsu N; Koeda Y; Morino Y; Nikaido A; Hata Y; Doi M; Hibi K; Kimura K; Yoda S; Kaneko T; Nishida K; Kawai K; Yamaguchi K; Wakatsuki T; Tonoike N; Yamamoto M; Shimizu S; Shimohama T; Ako J; Kimura T;
    Cardiovasc Interv Ther; 2021 Oct; 36(4):403-415. PubMed ID: 33184726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic determinants of clopidogrel responsiveness in Koreans treated with drug-eluting stents.
    Park JJ; Park KW; Kang J; Jeon KH; Kang SH; Ahn HS; Han JK; Koh JS; Lee SE; Yang HM; Lee HY; Kang HJ; Koo BK; Oh BH; Park YB; Kim HS
    Int J Cardiol; 2013 Feb; 163(1):79-86. PubMed ID: 23260377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study for the characterization of pharmacogenetically relevant CYP2D6, CYP2C19 and ABCB1 gene polymorphisms in the Hungarian population.
    Rideg O; Háber A; Botz L; Szücs F; Várnai R; Miseta A; Kovács GL
    Cell Biochem Funct; 2011 Oct; 29(7):562-8. PubMed ID: 21826689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
    Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
    Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
    Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotype-phenotype analysis of CYP2C19 in healthy saudi individuals and its potential clinical implication in drug therapy.
    Saeed LH; Mayet AY
    Int J Med Sci; 2013; 10(11):1497-502. PubMed ID: 24046523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.
    Jeong YH; Tantry US; Kim IS; Koh JS; Kwon TJ; Park Y; Hwang SJ; Bliden KP; Kwak CH; Hwang JY; Gurbel PA
    Circ Cardiovasc Interv; 2011 Dec; 4(6):585-94. PubMed ID: 22045970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Diagnostic Utility of the Point-of-Care CYP2C19 Genotyping Assay in Patients with Acute Coronary Syndrome Dosing Clopidogrel: Comparison with Platelet Function Test and SNP Genotyping.
    Choi JL; Kim BR; Woo KS; Kim KH; Kim JM; Kim MH; Han JY
    Ann Clin Lab Sci; 2016 Sep; 46(5):489-94. PubMed ID: 27650615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes.
    Nagashima Z; Tsukahara K; Morita S; Endo T; Sugano T; Hibi K; Himeno H; Fukui K; Umemura S; Kimura K
    J Cardiol; 2013 Sep; 62(3):158-64. PubMed ID: 23886632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
    Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
    Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
    Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects.
    Kobayashi M; Kajiwara M; Hasegawa S
    J Atheroscler Thromb; 2015; 22(11):1186-96. PubMed ID: 26063503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.